Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...

The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan Healthcare Conference. Among these, Moderna MRNA and ...

Study explains long-standing question of why Huntington’s disease symptoms typically do not appear until midlife even though ...

Failed to fetch dynamically imported module: https://ca.finance.yahoo.com/assets/_app/immutable/nodes/30.B7yWvFKE.js ...

In 2024, the Hatch-Waxman Act continued to play a critical role in the U.S. pharmaceutical landscape, driving the dynamics between ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

As the health care sector embraces AI, the incoming administration confronts some pressing challenges about what to regulate, ...

As the bull market enters its third year, the Sevens Report sees little reason for bearishness despite stretched valuations ...

Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31, 2025. In a presentation at the 43rd Annual J.P.